Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression

Lynn Longmore, John P. Foley, Thomas A. Rozanski, Betsy Higgins, Ian M Thompson

Resultado de la investigación: Articlerevisión exhaustiva

7 Citas (Scopus)

Resumen

Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. It is generally hypothesized to be due to a point mutation in the androgen receptor that allows the antiandrogen to function as an agonist, leading to a dramatic and rapid PSA response. We describe a patient with androgen-independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal. With continuing fall in PSA, the patient had unequivocal progression of disease seen on bone scan. This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal. It also illustrates the need for continued clinical evaluation of patients with metastatic prostate cancer, even in the face of PSA response.

Idioma originalEnglish (US)
Páginas (desde-hasta)573-575
Número de páginas3
PublicaciónSouthern medical journal
Volumen91
N.º6
DOI
EstadoPublished - jun. 1998

ASJC Scopus subject areas

  • Medicine(all)

Huella

Profundice en los temas de investigación de 'Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression'. En conjunto forman una huella única.

Citar esto